Full Press Release Details
Theranostics reports Fiscal Year 2025 Financial Results and Business Update
On track to complete enrollment of first two
cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177
On track to complete enrollment of the first
cohort of Phase 1 HEAT' trial of RAD202 for treatment of advanced HER2-positive solid tumors
U.S. FDA granted Fast Track Designation for
RAD101 to distinguish between recurrent disease and the treatment effect of brain metastases
Confirmed guidance of Cash Runway through to
Sydney, Australia - 29 July 2025 -
Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical
company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced financial
results for the fiscal year ended June 30, 2025, and provided a corporate update.
"During the last quarter, we continued to
execute with discipline and momentum across our pipeline, advancing key milestones within both our therapeutic and diagnostic radiopharmaceutical
programs," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "We are encouraged by the pace and
efficiency of our development efforts. Notable achievements this quarter include the FDA's Fast Track Designation for RAD101, DSMC
clearance to proceed with higher dosing of RAD204, procurement of multiple supply agreements for key radioisotopes and meaningful clinical
progress across our clinical pipeline. These milestones reflect our unwavering commitment to delivering precise, targeted radiopharmaceutical
solutions that have the potential to transform cancer care. Looking ahead, we anticipate a number of important clinical and corporate
milestones throughout the remainder of 2025."
Program and Business Updates
177Lu-RAD204 - Nanobody targeting PD-L1
radiolabeled with Lutetium 177
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
177Lu-RAD202 - Nanobody targeting HER2
radiolabeled with Lutetium 177
18F-RAD101 - Small molecule targeting
fatty acid synthase radiolabeled with Fluorine-18
Ga68-RAD301 - Peptide targeting v -integrin
radiolabeled with Gallium 68
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
The following is a summary of the Appendix 4C
In compliance with Listing Rule 4.7C, payments
to related parties and their associates, as detailed in item 6.1 of Appendix 4C, encompass remuneration for director fees to executive
and non-executive directors, conducted in the ordinary course of business at commercial rates, excluding reimbursements for out-of-pocket
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics
company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas
of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly
differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program
includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com.
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
Authorized on behalf of the Radiopharm
Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
CEO & Managing Director
Precision AQ (formerly Stern IR)
Follow Radiopharm Theranostics:
Website - https://radiopharmtheranostics.com/
InvestorHub - https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
cash flow report for entities subject to Listing Rule 4.7B
| Name of entity | ||
| Radiopharm Theranostics Limited | ||
| ABN | Quarter ended ("current quarter") | |
| 57 647 877 889 | 30 June 2025 |
| Consolidated statement of cash flows | Current quarter $A'000 | Year to date (12 months) $A'000 | ||||||||
| 1. | Cash flows from operating activities | 829 | 5,366 | |||||||
| 1.1 | Receipts from customers | |||||||||
| 1.2 | Payments for | (4,759 | ) | (28,393 | ) | |||||
| (a) research and development | ||||||||||
| (b) product manufacturing and operating costs | - | - | ||||||||
| (c) advertising and marketing | (119 | ) | (276 | ) | ||||||
| (d) leased assets | - | - | ||||||||
| (e) staff costs | (2,406 | ) | (10,482 | ) | ||||||
| (f) administration and corporate costs | (922 | ) | (4,412 | ) | ||||||
| 1.3 | Dividends received (see note 3) | - | - | |||||||
| 1.4 | Interest received | 193 | 800 | |||||||
| 1.5 | Interest and other costs of finance paid | - | (44 | ) | ||||||
| 1.6 | Income taxes paid | - | - | |||||||
| 1.7 | Government grants and tax incentives | - | - | |||||||
| 1.8 | Other - GST refunded | 157 | 771 | |||||||
| 1.9 | Net cash from / (used in) operating activities | (7,027 | ) | (36,670 | ) |
| ASX Listing Rules Appendix 4C (17/07/20) | Page 1 |
| + See chapter 19 of the ASX Listing Rules for defined terms. |
Quarterly cash flow report for entities subject to Listing Rule 4.7B
| Consolidated statement of cash flows | Current quarter $A'000 | Year to date (12 months) $A'000 | ||||||||
| 2. | Cash flows from investing activities | |||||||||
| 2.1 | Payments to acquire or for: | |||||||||
| (a) entities | - | - | ||||||||
| (b) businesses | - | - | ||||||||
| (c) property, plant and equipment | - | - | ||||||||
| (d) investments | - | - | ||||||||
| (e) intellectual property | - | - | ||||||||
| (f) other non-current assets | - | - | ||||||||
| 2.2 | Proceeds from disposal of: | |||||||||
| (a) entities | - | - | ||||||||
| (b) businesses | - | - | ||||||||
| (c) property, plant and equipment | - | - | ||||||||
| (d) investments | - | - | ||||||||
| (e) intellectual property | - | 2,995 | ||||||||
| (f) other non-current assets | - | - | ||||||||
| 2.3 | Cash flows from loans to other entities | - | - | |||||||
| 2.4 | Dividends received (see note 3) | - | - | |||||||
| 2.5 | Other (provide details if material) | - | - | |||||||
| 2.6 | Net cash from / (used in) investing activities | - | 2,995 | |||||||
| 3. | Cash flows from financing activities | |||||||||
| 3.1 | Proceeds from issues of equity securities (excluding convertible debt securities) | - | 53,978 | |||||||
| 3.2 | Proceeds from issue of convertible debt securities | - | - | |||||||
| 3.3 | Proceeds from exercise of options | - | - | |||||||
| 3.4 | Transaction costs related to issues of equity securities or convertible debt securities | (472 | ) | (4,738 | ) | |||||
| 3.5 | Proceeds from borrowings | - | - | |||||||
| 3.6 | Repayment of borrowings | - | (1,900 | ) | ||||||
| 3.7 | Transaction costs related to loans and borrowings | - | (219 | ) | ||||||
| 3.8 | Dividends paid | - | - | |||||||
| 3.9 | Other - payments of license fee liabilities and settlement fees | - | (2,928 | ) | ||||||
| 3.10 | Net cash from / (used in) financing activities | (472 | ) | 44,193 |
| ASX Listing Rules Appendix 4C (17/07/20) | Page 2 |
| + See chapter 19 of the ASX Listing Rules for defined terms. |
Quarterly cash flow report for entities subject to Listing Rule 4.7B
| Consolidated statement of cash flows | Current quarter $A'000 | Year to date (12 months) $A'000 | ||||||||
| 4. | Net increase / (decrease) in cash and cash equivalents for the period | |||||||||
| 4.1 | Cash and cash equivalents at beginning of period | 36,864 | 18,575 | |||||||
| 4.2 | Net cash from / (used in) operating activities (item 1.9 above) | (7,027 | ) | (36,670 | ) | |||||
| 4.3 | Net cash from / (used in) investing activities (item 2.6 above) | - | 2,995 | |||||||
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | (472 | ) | 44,193 | ||||||
| 4.5 | Effect of movement in exchange rates on cash held | (248 | ) | 24 | ||||||
| 4.6 | Cash and cash equivalents at end of period | 29,117 | 29,117 |
| 5. | Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter $A'000 | Previous quarter $A'000 | |||||||
| 5.1 | Bank balances | 29,117 | 36,864 | |||||||
| 5.2 | Call deposits | - | - | |||||||
| 5.3 | Bank overdrafts | - | - | |||||||
| 5.4 | Other (provide details) | - | - | |||||||
| 5.5 | Cash and cash equivalents at end of quarter (should equal item 4.6 above) | 29,117 | 36,864 |
| 6. | Payments to related parties of the entity and their associates | Current quarter $A'000 | ||||
| 6.1 | Aggregate amount of payments to related parties and their associates included in item 1 | 555 | ||||
| 6.2 | Aggregate amount of payments to related parties and their associates included in item 2 | - |
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.
In accordance with Listing Rule 4.7C, payments made to related parties
and their associates included in items 6.1 of the Appendix 4C includes compensation and director fee related payments in the normal course
of business at commercial rates, excluding reimbursements of out-of-pocket expenses.
| ASX Listing Rules Appendix 4C (17/07/20) | Page 3 |
| + See chapter 19 of the ASX Listing Rules for defined terms. |
Quarterly cash flow report for entities subject to Listing Rule 4.7B
| 7. | Financing facilities Note: the term "facility' includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity. | Total facility amount at quarter end $A'000 | Amount drawn at quarter end $A'000 | |||||||
| 7.1 | Loan facilities | - | - | |||||||
| 7.2 | Credit standby arrangements | - | - | |||||||
| 7.3 | Other (please specify) | - | - | |||||||
| 7.4 | Total financing facilities | - | - | |||||||
| 7.5 | Unused financing facilities available at quarter end | - | ||||||||
| 7.6 | Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. | |||||||||
| N/A |
| 8. | Estimated cash available for future operating activities | $A'000 | ||||
| 8.1 | Net cash from / (used in) operating activities (item 1.9) | (7,027 | ) | |||
| 8.2 | Cash and cash equivalents at quarter end (item 4.6) | |||||
| 8.3 | Unused finance facilities available at quarter end (item 7.5) | - | ||||
| 8.4 | Total available funding (item 8.2 + item 8.3) | 29,117 | ||||
| 8.5 | Estimated quarters of funding available (item 8.4 divided by item 8.1) | 4 |
| ASX Listing Rules Appendix 4C (17/07/20) | Page 4 |
| + See chapter 19 of the ASX Listing Rules for defined terms. |
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
(Name of body or officer authorising release - see
| ASX Listing Rules Appendix 4C (17/07/20) | Page 5 |
| + See chapter 19 of the ASX Listing Rules for defined terms. |